PDL BioPharma, Inc. Income from Discontinued Operations

Income from Discontinued Operations of PDLI for past 10 years: annual, quarterly and twelve month trailing (TTM) including Income from Discontinued Operations growth rates and interactive chart.


Highlights and Quick Summary

  • Income from Discontinued Operations for the quarter ending June 29, 2020 was $-37.4 Million (a 15227.46% increase compared to previous quarter)
  • Year-over-year quarterly Income from Discontinued Operations decreased by -348.19%
  • Twelve month Income from Discontinued Operations ending June 29, 2020 was $-19.1 Million
Trailing Income from Discontinued Operations for the last four month:
29 Jun '20
$-19.1 Million
Visit stockrow.com/PDLI for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Income from Discontinued Operations of PDL BioPharma, Inc.

Most recent Income from Discontinued Operationsof PDLI including historical data for past 10 years.

Interactive Chart of Income from Discontinued Operations of PDL BioPharma, Inc.

PDL BioPharma, Inc. Income from Discontinued Operations for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $-37.4 $-0.24
2019 $3.5 $15.07

Business Profile of PDL BioPharma, Inc.

Sector: Other
Industry: Other
PDL BioPharma, Inc. manages various patents in the United States and internationally. The company's patents cover humanization of antibodies. It also offers notes and other long-term receivables services, as well as engages in the equity investment activities. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.